Information de reference pour ce titreAccession Number: | 00078402-201509151-00020.
|
Author: | Qin, Mei; Zeidler, Zachary; Moulton, Kristen; Krych, Leland; Xia, Zengyan; Smith, Carolyn B. *
|
Institution: | Section on Neuroadaptation and Protein Metabolism, National Institute of Mental Health, National Institutes of Health, 10 Center Drive, Bldg. 10, Rm. 2D54, Bethesda, MD 20892, USA
|
Title: | Endocannabinoid-mediated improvement on a test of aversive memory in a mouse model of fragile X syndrome.[Report]
|
Source: | Behavioural Brain Research. 291 (Supplement C):164-171, September 15, 2015.
|
Abstract: | : Silencing the gene FMR1 in fragile X syndrome (FXS) with consequent loss of its protein product, FMRP, results in intellectual disability, hyperactivity, anxiety, seizure disorders, and autism-like behavior. In a mouse model (Fmr1 knockout (KO)) of FXS, a deficit in performance on the passive avoidance test of learning and memory is a robust phenotype. We report that drugs acting on the endocannabinoid (eCB) system can improve performance on this test. We present three lines of evidence: (1) Propofol (reported to inhibit fatty acid amide hydrolase (FAAH) activity) administered 30 min after training on the passive avoidance test improved performance in Fmr1 KO mice but had no effect on wild type (WT). FAAH catalyzes the metabolism of the eCB, anandamide, so its inhibition should result in increased anandamide levels. (2) The effect of propofol was blocked by prior administration of the cannabinoid receptor 1 antagonist AM-251. (3) Treatment with the FAAH inhibitor, URB-597, administered 30 min after training on the passive avoidance test also improved performance in Fmr1 KO mice but had no effect on WT. Our results indicate that the eCB system is involved in FXS and suggest that the eCB system is a promising target for treatment of FXS.
(C) 2015Elsevier, Inc.
|
Author Keywords: | Fragile X syndrome; FAAH; Passive avoidance; Propofol; Fmr1 KO mice; Memory.
|
References: | [1] Darnell JC, Van Driesche SJ, Zhang C, Hung KY, Mele A, Fraser CE, et al. FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. Cell. 2011;146:247-261.
[2] Qin M, Kang J, Burlin TV, Jiang C, Smith CB. Post-adolescent changes in regional cerebral protein synthesis: an in vivo study in the Fmr1 null mouse. J Neurosci. 2005;25:5087-5095.
[3] Qin M, Schmidt KC, Zametkin AJ, Bishu S, Horowitz LM, Burlin TV, et al. Altered cerebral protein synthesis in fragile X syndrome: studies in human subjects and knockout mice. J Cereb Blood Flow Metab. 2013;33:499-507.
[4] Bishu S, Schmidt KC, Burlin TV, Channing MA, Horowitz L, Huang T, et al. Propofol anesthesia does not alter regional rates of cerebral protein synthesis measured with L-[1-11C]leucine and PET in healthy male subjects. J Cereb Blood Flow Metab. 2009;29:1035-1047.
[5] Qin M, Kang J, Smith CB. Increased rates of cerebral glucose metabolism in a mouse model of fragile X mental retardation. Proc Natl Acad Sci U S A. 2002;99:15758-15763.
[6] Liu ZH, Chuang DM, Smith CB. Lithium ameliorates phenotypic deficits in a mouse model of fragile X syndrome. Int J Neuropsychopharmacol. 2011;14:618-630.
[7] Ding Q, Sethna F, Wang H. Behavioral analysis of male and female Fmr1 knockout mice on C57BL/6 background. Behav Brain Res. 2014;271:72-78.
[8] Hauer D, Ratano P, Morena M, Scaccianoce S, Briegel I, Palmery M, et al. Propofol enhances memory formation via an interaction with the endocannabinoid system. Anesthesiology. 2011;114:1380-1388.
[9] Trapani G, Altomare C, Liso G, Sanna E, Biggio G. Propofol in anesthesia. Mechanism of action, structure-activity relationships, and drug delivery. Curr Med Chem. 2000;7:249-271.
[10] Patel S, Wohlfeil ER, Rademacher DJ, Carrier EJ, Perry LJ, Kundu A, et al. The general anesthetic propofol increases brain N-arachidonylethanolamine (anandamide) content and inhibits fatty acid amide hydrolase. Br J Pharmacol. 2003;139:1005-1013.
[11] Maccarrone M, Rossi S, Bari M, De Chiara V, Rapino C, Musella A, et al. Abnormal mGlu 5 receptor/endocannabinoid coupling in mice lacking FMRP and BC1 RNA. Neuropsychopharmacology. 2010;35:1500-1509.
[12] Zhang L, Alger BE. Enhanced endocannabinoid signaling elevates neuronal excitability in fragile X syndrome. J Neurosci. 2010;30:5724-5729.
[13] Jung KM, Sepers M, Henstridge CM, Lassalle O, Neuhofer D, Martin H, et al. Uncoupling of the endocannabinoid signalling complex in a mouse model of fragile X syndrome. Nat Commun. 2012;3:1080.
[14] Busquets-Garcia A, Gomis-Gonzalez M, Guegan T, Agustin-Pavon C, Pastor A, Mato S, et al. Targeting the endocannabinoid system in the treatment of fragile X syndrome. Nat Med. 2013;19:603-607.
[15] Straiker A, Min KT, Mackie K. Fmr1 deletion enhances and ultimately desensitizes CB(1) signaling in autaptic hippocampal neurons. Neurobiol Dis. 2013;56:1-5.
[16] Detrait E, Hanon E, Dardenne B, Lamberty Y. The inhibitory avoidance test optimized for discovery of cognitive enhancers. Behavior Res Methods. 2009;41:805-811.
[17] Liu ZH, Smith CB. Dissociation of social and nonsocial anxiety in a mouse model of fragile X syndrome. Neurosci Lett. 2009;454:62-66.
[18] Mazzola C, Medalie J, Scherma M, Panlilio LV, Solinas M, Tanda G, et al. Fatty acid amide hydrolase (FAAH) inhibition enhances memory acquisition through activation of PPAR-alpha nuclear receptors. Learn Mem. 2009;16:332-337.
[19] Hill MN, Kumar SA, Filipski SB, Iverson M, Stuhr KL, Keith JM, et al. Disruption of fatty acid amide hydrolase activity prevents the effects of chronic stress on anxiety and amygdalar microstructure. Mol Psychiatry. 2013;18:1125-1135.
[20] Gray JM, Vecchiarelli HA, Morena M, Lee TT, Hermanson DJ, Kim AB, et al. Corticotropin-releasing hormone drives anandamide hydrolysis in the amygdala to promote anxiety. J Neurosci. 2015;35:3879-3892.
[21] Mines MA, Yuskaitis CJ, King MK, Beurel E, Jope RS. GSK3 influences social preference and anxiety-related behaviors during social interaction in a mouse model of fragile X syndrome and autism. PLoS One. 2010;5:e9706.
[22] Heitzer AM, Roth AK, Nawrocki L, Wrenn CC, Valdovinos MG. Brief report: altered social behavior in isolation-reared Fmr1 knockout mice. J Autism Dev Disord. 2013;43:1452-1458.
[23] Kano M, Ohno-Shosaku T, Hashimotodani Y, Uchigashima M, Watanabe M. Endocannabinoid-mediated control of synaptic transmission. Physiol Rev. 2009;89:309-380.
[24] Tang AH, Alger BE. Homer protein-metabotropic glutamate receptor binding regulates endocannabinoid signaling and affects hyperexcitability in a mouse model of fragile X syndrome. J Neurosci. 2015;35:3938-3945.
[25] Ronesi JA, Huber KM. Homer interactions are necessary for metabotropic glutamate receptor-induced long-term depression and translational activation. J Neurosci. 2008;28:543-547.
[26] Melis M, Greco B, Tonini R. Interplay between synaptic endocannabinoid signaling and metaplasticity in neuronal circuit function and dysfunction. Eur J Neurosci. 2014;39:1189-1201.
|
Language: | English.
|
Document Type: | Research report.
|
Journal Subset: | Clinical Medicine. Behavioral & Social Sciences.
|
ISSN: | 0166-4328
|
DOI Number: | https://dx.doi.org/10.1016/j.bbr...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|